Skip to main content

Physiologically Based Pharmacokinetic Modelling, an Integrative Approach to First in Human (FIH) Studies [APAC Webinar]

Physiologically Based Pharmacokinetic (PBPK) modelling is an integrative approach facilitating the optimal use of various in vitro and preclinical data to determine the first in human dose.

Simcyp Discovery, a part of Simcyp family, is a user-friendly PBPK platform designed to integrate in vitro and preclinical data, enabling the prediction of drug pharmacokinetics (PK) in rats, mice, dogs, monkeys, and humans. This platform helps reduce the reliance on animal studies, assess early formulations, investigate drug interaction risks, and provide robust first-in-human dose predictions.

Watch as our PBPK consultancy team presents real-world case studies demonstrating the practical applications and benefits of this approach. The case studies include compound selection, improvement over competitor drug, parent and metabolite modelling and drug-drug interaction risk assessment overall enhancing the IND filing.

For whom the webinar will be beneficial the most:

    • DMPK scientists at pharma/biopharma

    • Any researchers who are interested in PBPK modeling for early drug development and pre-IND

    • Simcyp users and non-Simcyp users who are interested in case studies of FIH

Speaker: 

    • Noriko Okudaira, PhD, Sr PBPK Consultant, Certara